MedTrace Logo

In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis

NCT03337945 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-05-23

No results posted yet for this study

Summary

Subjects will receive the "Basel phenotyping cocktail" capsule orally with 120-200ml tap water in fasted state. After intake peripheral venous blood samples will be drawn.

12 patients (male and female) with liver cirrhosis for each Child Pugh Category A, B, and C, and 12 age- and gender-matched healthy control subjects will be included (in total 48 participants).

Conditions

Interventions

DRUG

"Basel phenotyping cocktail" capsule

Oral intake of "Basel phenotyping cocktail" capsule and pharmacokinetics (PK) sampling

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Stephan Krähenbühl · Universitätsspital Basel, Switzerland

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-04
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03337945 on ClinicalTrials.gov